AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03940287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape application
Description: Kinesiotaping will be applied to piriformis muscle and Sacroiliac joint (SIJ). This tape will be applied in I shape to both sides of the spine from sacrum to Anterior Superior Iliac Spine. For SIJ taping same 5 cm KT tape will be used, it will be applied from below posterior sacroiliac spine to opposite side. Here patient should be in standing position.~For Piriformis application patient will be in side lying position where the affected leg will be placed uppermost with hip in flexion, adduction, and internal rotation , then the application will be performed. The base of the tape will be placed over contralateral part of sacrum and then make a Y strip with no tension will be attached over the greater trochanter of femur.
Study NCT03940287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Hydro-collator pack will be used superior to the affected area for at-least 15 minute to reduce the stiffness. Hydocollator pack will be wrap twice with a thick towel and then it will be placed to the affected part.
Study NCT02055833 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intensive nutritional counseling
Description: Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
Study NCT02055833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling
Study NCT01956435 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Excimer Light Treatment
Description: Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
Study NCT03734575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariCore System
Description: The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
Study NCT01854658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)
Description: GFF MDI administered as two puffs BID
Study NCT01854658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP MDI (PT001)
Description: GP MDI administered as two puffs BID
Study NCT01854658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI (PT005)
Description: FF MDI administered as two puffs BID
Study NCT03093610 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
Study NCT03093610 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Test
Description: Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
Study NCT03916614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Tool for Relief of Trauma (START)
Description: The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,\[30\] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
Study NCT03916614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
Study NCT02324114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hsp90
Description: Detect plasma Hsp90α concentration
Study NCT03572413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum
Description: Lowering intra-abdominal pressure during laparoscopic surgery
Study NCT03572413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
Study NCT03572413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide
Description: Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
Study NCT04702503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WP1220
Description: Topical administration 2x daily for 84 consecutive days
Study NCT03412942 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FISH SP
Description: The device will be used to close the femoral artery after angiogram and/or endovascular procedure.
Study NCT03910543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Description: Tofacitinib will be administered at a dose of 5 mg twice daily
Study NCT01430702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)
Description: The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
Study NCT03766438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Storytelling Intervention
Description: 12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
Study NCT04290429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Treatment of patients with SR-GI-GVHD with teduglutide
Study NCT02653079 — intervention group
Intervention type: OTHER
Intervention: Blood Draw and Questionaire
Description: The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
Study NCT01249300 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03465488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole Pill 400mg (GSK)
Description: One single dose of 400mg Albendazole is provided at baseline.
Study NCT00486733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaGold
Description: The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
Study NCT02556034 — intervention group
Intervention type: OTHER
Intervention: Disease evaluation.
Description: Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
Study NCT02714803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connective tissue massage and Conservative applications
Description: Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
Study NCT02714803 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classic massage group and Conservative applications
Description: Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
Study NCT02714803 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham massage group and Conservative applications
Description: Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
Study NCT01606384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)
Description: Pharmaceutical form: Capsule Route of administration: oral
Study NCT01606384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT03238482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol-fluticasone
Description: Seretide Diskus 50/250 µg/dose
Study NCT03238482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol-fluticasone
Description: Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
Study NCT03238482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol-fluticasone
Description: Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
Study NCT03238482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol-fluticasone
Description: Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
Study NCT03645174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using long tube
Description: Fiberoptic-guided intubation through LMA, using long tube
Study NCT03645174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aintree catheter
Description: Fiberoptic-guided intubation through LMA, using Aintree catheter
Study NCT04551417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free graft urethroplasty
Description: Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
Study NCT04551417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free graft urethroplasty
Description: Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
Study NCT04470102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve repair by edge-to-edge technique
Description: transaortic access for mitral valve repair edge-to-edge
Study NCT04470102 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Septal myectomy
Description: isolated extended septal myectomy
Study NCT02195557 — intervention group
Intervention type: DRUG
Intervention: Synvisc®
Study NCT03826602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 150mg administered orally twice daily
Study NCT03826602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850mg administered orally
Study NCT03826602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: 1500 mg administered intravenously (IV)
Study NCT04668183 — intervention group
Intervention type: PROCEDURE
Intervention: Pudendal nerve block group
Description: A 22 Gauge 50 mm insulated needle was then introduced in the anterior-posterior direction at the middle of the ultrasound probe's superior edge with an out-of-plane approach and using an inclination of 15° in the sagittal plane. The needle tip's position was identified by direct visualization using the movement of adjacent anatomical structures.
Study NCT04668183 — intervention group
Intervention type: PROCEDURE
Intervention: Dorsal penile nerve block group
Description: Half of the total 0.2 ml/kg dose of 0.25% bupivacaine was administered while observing its distribution with US. The same procedure was then repeated on the other side of the penis.
Study NCT06368180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted gait training
Description: is a robotic treadmill training system that uses body weight support to suspend patients by attaching their legs to robotic legs that help them walk
Study NCT06368180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body weight supported treadmill training
Description: The Biodex Unweighting System was used to support the child's body weight, by an adjustable harness placed, over the treadmill.
Study NCT00782041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m²
Study NCT00782041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FluoroUracil
Description: 2,000 mg/m²
Study NCT00782041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: 20 mg/m²
Study NCT03683862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic appliance
Description: Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
Study NCT03683862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic appliance
Description: Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
Study NCT02214667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-diagnosis motivational interviewing (DDMI)
Description: DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
Study NCT02214667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated group therapy (IGT)
Description: IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
Study NCT02214667 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Jail and community-based behavioral health services
Description: Existing behavioral health service programs
Study NCT00349908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cordis Neurovascular ENTERPRISE Self Expanding Stent System
Description: Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
Study NCT00349908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cordis Neurovascular ENTERPRISE Self Expanding Stent System
Description: Implantation of the device ENTERPRISE to treat wide-necked aneurysms
Study NCT03737175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting
Study NCT03737175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Endarterectomy
Description: Carotid Endarterectomy
Study NCT00931229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
Study NCT00326027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Efficacy of Pantoprazole
Study NCT03045692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: kidney function assessment by 4 hour creatinine clearance
Description: 4 hour creatinine clearance is used to decide colistin maintenance dosage.
Study NCT03045692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: kidney function assessment by creatinine based eGFR
Description: creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
Study NCT00926393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine Immediate Release
Description: Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
Study NCT00926393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine Extended Release
Description: Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
Study NCT01749787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 1.5 mcg/kg
Study NCT01749787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 3.0 mcg/kg
Study NCT01749787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 6.0 mcg/kg
Study NCT01749787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 12.0 mcg/kg
Study NCT01749787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 240 mcg
Study NCT01884064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS
Study NCT01854658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02339285 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS (alpha)
Study NCT02339285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS (alpha)
Study NCT02339285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS (gamma)
Study NCT03832777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Subjects will receive both active and placebo rTMS, in a crossover modality.
Study NCT03832777 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Subjects will receive both active and placebo rTMS, in a crossover modality.
Study NCT00515229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amitriptyline
Description: Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch
Study NCT00515229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amitriptyline
Description: Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch
Study NCT04031508 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: lipid injectable emulsion with Fish oil
Description: TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.
Study NCT04031508 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: lipid injectable emulsion with Fish oil
Description: TPN will start at 1.5-2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 3.0 g/kg/d for at least 7 days.
Study NCT03140969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-110
Description: RNA antisense oligonucleotide for intravitreal injection
Study NCT01969058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
Study NCT02708901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx®
Description: Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
Study NCT02708901 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
Study NCT03878238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bths-003
Description: Probiotic with maltodextrin as a carrier.
Study NCT03878238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with maltodextrin base.
Study NCT02322073 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Roux-en-Y gastric bypass or other benign laparoscopic surgery
Study NCT02834728 — intervention group
Intervention type: BEHAVIORAL
Intervention: telephone interview
Study NCT03835871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention: Drug: placebo
Study NCT03835871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention: Drug: placebo
Study NCT03835871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 µg per day Beclomethasone
Description: Intervention: Drug: Beclomethasone 400 µg HFA per day
Study NCT03835871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 µg per day Beclomethasone
Description: Intervention: Drug: Beclomethasone 200 µg HFA per day
Study NCT03835871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 µg per day Beclomethasone
Description: Intervention: Drug: Beclomethasone 100 µg HFA per day
Study NCT05890144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Big Canoe
Description: The Big Canoe will involve an intensive, multi-modular Indigenous cultural safety education training program that is offered online and led by trained facilitators. It is 10 modules long and takes 10 weeks to complete (1 hour of learning per week).